New Frontiers in Immuno-Oncology for Microsatellite-Instability-High Cancers
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclaimer

Not an official event of the 2017 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Merck Sharp & Dohme Corp.

New Frontiers in Immuno-Oncology for Microsatellite-Instability-High Cancers


Monday, June 5, 2017
7:00 PM - 9:00 PM

Dinner and registration: 6:30 PM – 7:00 PM

Hilton Chicago
International Ballroom North (Lobby Level)
720 S Michigan Avenue
Chicago, IL 60605

Overview

The significance of deficiencies in mismatch repair (dMMR) pathways and microsatellite instability (MSI) toward the delivery of precision cancer care is evolving. Mismatch repair deficiencies and MSI are important components in the pathogenesis of certain solid tumors that carry both prognostic and predictive value. Results from clinical studies suggest that a variety of solid tumors that are dMMR/MSI-high (MSI-H) phenotype respond to immune checkpoint inhibition more than MMR-proficient tumors, and have prompted further studies in this area. Additionally, results of ongoing research may lead to use of dMMR/MSI testing to predict response to immunotherapy across tumor types. These investigations have the potential to impact a broad number of solid tumor types, with immunotherapy being delivered based on genetic composition (ie, MSI-H) versus tumor type. New Frontiers in Immuno-Oncology for Microsatellite-Instability-High Cancers is a CME-certified, live symposium to be held adjunct to an annual oncology meeting in Chicago, Illinois. We invite you to join a renowned group of experts in the treatment of MSI-H tumors as they guide participants through this fascinating and potentially practice-transforming application of immunotherapy.

Key topics on the agenda include:

  • dMMR/MSI testing and potential role as a predictive marker in solid tumors
  • Immunogenicity of dMMR/MSI-H tumors
  • Emerging clinical trial data regarding the use of immunotherapy for dMMR/MSI-H tumors
  • Patient‒provider communication regarding dMMR/MSI-H status

Target Audience

This educational activity is directed toward medical oncologists who treat patients with solid tumors. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of solid tumors also are invited to participate.

Learning Objectives

Upon completion of this activity, participants should be better prepared to:

  1. Explain the evolving roles for mismatch repair (MMR) deficiency and microsatellite instability (MSI) testing in clinical oncology practice
  2. Describe the relationship between MSI status and immunologic response, including evidence concerning the use of MSI as a predictive marker for response to checkpoint blockade
  3. Evaluate current and emerging clinical trial results concerning the use of immunotherapeutic approaches in patients with MSI-H tumors
  4. Delineate next steps in the field concerning the use of novel treatment strategies for the management of MSI-H cancers


Program Chair

Wells Messersmith, MD, FACP
Professor and Head, Division of Medical Oncology
Director, GI Medical Oncology Program
Co-Leader, Developmental Therapeutics Program
University of Colorado Cancer Center
University of Colorado School of Medicine
Denver, CO


Calendar of Events
SUNMONTUESWEDTHURSFRISAT
    123
45678910
11121314151617
18192021222324
252627282930
Filter By